April 03, 2025

FDA Reaches Decision on Reproxalap

The FDA’s Complete Response Letter recommends an additional trial that focuses on DED symptoms.

Conexiant

April 01, 2025

Cemiplimab Effective for Advanced cSCC

Meta-analysis of 19 studies reveals promising 54.5% objective response rate and manageable safety profile for PD-1 inhibitor in treating advanced cutaneous squamous cell carcinoma.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 27, 2025

Trends in Spironolactone Prescribing Among Young Women

A cohort study of 38 million insured females aged 12 to 40 years found a marked increase in spironolactone prescriptions, most commonly for acne and other androgen-related conditions.

Conexiant

March 26, 2025

Anesthesiologist Facing Attempted Murder Charges

An anesthesiologist has been apprehended in Hawaii after allegedly assaulting his spouse at a popular hiking location, resulting in the closure of the Nu'uanu Pali State Wayside.

Conexiant

March 25, 2025

Does Bicalutamide Help Hair Loss?

A new randomized clinical trial found no added benefit from combining bicalutamide with minoxidil in the treatment of female pattern hair loss, contrasting with findings from previous retrospective studies and noting that further research on antiandrogen therapy is needed.

Conexiant

March 24, 2025

HS Guidelines for Special Populations

"These guidelines address the unique needs of diverse groups typically underrepresented in clinical trials, and highlight the importance of a multidisciplinary approach."

Conexiant

March 24, 2025

Tildrakizumab Shows Lasting Efficacy in Scalp Psoriasis

Tildrakizumab may provide durable response for scalp psoriasis, a phase 3b study found, confirming sustained efficacy and safety through 52 weeks.

Conexiant

March 21, 2025

Biosimilars Match Adalimumab Originator Efficacy for Psoriasis

Amjevita and Imraldi were as effective as Humira for both new starters and patients switching from Humira, researchers concluded

Conexiant